在随机对照试验的荟萃分析中纳入干预措施的非随机研究,改变了超过三分之一研究中的估计值:来自实证分析的证据。

Including non-randomized studies of interventions in meta-analyses of randomized controlled trials changed the estimates in more than a third of the studies: evidence from an empirical analysis.

作者信息

Yao Minghong, Mei Fan, Ma Yu, Qin Xuan, Huan Jiayidaer, Zou Kang, Li Ling, Sun Xin

机构信息

Department of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, West China Hospital, Sichuan University, Chengdu, China; Sichuan Center of Technology Innovation for Real World Data, West China Hospital, Sichuan University, Chengdu, China.

Department of Neurosurgery and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China; NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, West China Hospital, Sichuan University, Chengdu, China; Sichuan Center of Technology Innovation for Real World Data, West China Hospital, Sichuan University, Chengdu, China.

出版信息

J Clin Epidemiol. 2025 May 5;183:111815. doi: 10.1016/j.jclinepi.2025.111815.

Abstract

OBJECTIVES

There is a growing trend to include nonrandomized studies of interventions (NRSIs) in meta-analyses of randomized controlled trials (RCTs) for health decision-making. The study aimed to quantify the impact of integrating NRSI on the evidence derived from RCTs within the same systematic review.

STUDY DESIGN AND SETTING

We searched PubMed for systematic reviews published between December 9, 2017, and December 9, 2022, that included both RCTs and NRSIs under the same outcome. Using the DerSimonian-Laird random-effects model, we reanalyzed the pooled estimates to compare those derived from RCTs with those from combined RCTs and NRSIs. We examined changes in point estimates, subgroup differences, statistical heterogeneity, and the weight of RCTs in pooled estimates. Results were defined as being in qualitative agreement if both estimates demonstrated statistical significance in the same direction or if neither achieved statistical significance.

RESULTS

A total of 220 eligible systematic reviews were identified and 217 meta-analyses were reanalyzed. Qualitative disagreement between RCTs only and pooled estimates combining RCTs and NRSIs was observed in 78 meta-analyses (35.9%), of which 69 (88.5%) gained statistical significance after the inclusion of NRSIs. Point estimates in 58 meta-analyses (26.7%) failed to meet predefined agreement criteria, and statistically significant subgroup differences between RCTs and NRSIs were identified in 32 meta-analyses (14.8%). The incorporation of NRSIs raised the heterogeneity from 21.8% to 36.9%, whereas RCTs accounted for a median weight of 33.9% in the pooled estimates.

CONCLUSION

These findings highlight the need for caution in conducting and interpreting meta-analyses combining RCTs and NRSIs, particularly in scenarios where RCTs yield nonsignificant results whereas the inclusion of NRSIs achieves statistical significance.

PLAIN LANGUAGE SUMMARY

Although randomized controlled trials (RCTs) remain the gold standard for clinical evidence, they are often insufficient to address complex clinical questions. Nonrandomized studies of interventions (NRSIs), leveraging real-world clinical data, are increasingly used to supplement RCT findings. Despite growing interest in integrating NRSIs into meta-analyses with RCTs, the clinical and statistical implications of this approach remain uncertain. To address this gap, we conducted a systematic evaluation of how NRSI inclusion impacts meta-analytic results by analyzing 220 systematic reviews that combined RCTs and NRSIs under the same outcome. Our analysis revealed that incorporating NRSIs altered effect estimates in over one-third of cases, with 88.5% of meta-analyses achieving statistical significance only after NRSI inclusion-a finding with critical implications for decision-making. In addition, NRSI integration elevated statistical heterogeneity, although RCTs accounted for less than one-third of the weight in pooled estimates. These findings collectively underscore the necessity for robust evaluation and cautious interpretation when merging NRSI data with RCTs in meta-analyses.

摘要

目的

在用于健康决策的随机对照试验(RCT)的荟萃分析中纳入干预措施的非随机研究(NRSI)的趋势日益增长。本研究旨在量化在同一系统评价中纳入NRSI对源自RCT的证据的影响。

研究设计与背景

我们在PubMed中检索了2017年12月9日至2022年12月9日期间发表的系统评价,这些评价在同一结局下纳入了RCT和NRSI。使用DerSimonian-Laird随机效应模型,我们重新分析了合并估计值,以比较源自RCT的估计值与源自合并的RCT和NRSI的估计值。我们检查了点估计值的变化、亚组差异、统计异质性以及RCT在合并估计值中的权重。如果两个估计值在同一方向上均显示出统计学显著性,或者两者均未达到统计学显著性,则结果被定义为在定性上一致。

结果

共识别出220项符合条件的系统评价,并对217项荟萃分析进行了重新分析。在78项荟萃分析(35.9%)中观察到仅RCT与合并了RCT和NRSI的合并估计值之间存在定性分歧,其中69项(88.5%)在纳入NRSI后获得了统计学显著性。58项荟萃分析(26.7%)中的点估计值未达到预先定义的一致性标准,并且在32项荟萃分析(14.8%)中识别出RCT和NRSI之间存在统计学显著性的亚组差异。纳入NRSI使异质性从21.8%提高到36.9%,而在合并估计值中,RCT的中位数权重为33.9%。

结论

这些发现凸显了在进行和解释合并RCT和NRSI的荟萃分析时需要谨慎,特别是在RCT产生无显著性结果而纳入NRSI后达到统计学显著性的情况下。

通俗易懂的总结

尽管随机对照试验(RCT)仍然是临床证据的金标准,但它们往往不足以解决复杂的临床问题。利用真实世界临床数据的干预措施的非随机研究(NRSI)越来越多地用于补充RCT的结果。尽管将NRSI纳入与RCT的荟萃分析的兴趣日益浓厚,但这种方法的临床和统计学意义仍不确定。为了填补这一空白,我们通过分析220项在同一结局下合并了RCT和NRSI的系统评价,对纳入NRSI如何影响荟萃分析结果进行了系统评估。我们的分析表明,在超过三分之一的案例中,纳入NRSI改变了效应估计值,88.5%的荟萃分析仅在纳入NRSI后才达到统计学显著性——这一发现对决策具有关键意义。此外,纳入NRSI提高了统计异质性,尽管在合并估计值中RCT占比不到三分之一。这些发现共同强调了在荟萃分析中将NRSI数据与RCT合并时进行有力评估和谨慎解释的必要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索